Propanc Biopharma Secures $100 Million Financing Agreement with Hexstone Capital

Propanc Biopharma has entered a strategic financing agreement of up to $100 million with Hexstone Capital. The agreement includes the issuance of Series C Convertible Preferred Stock and Warrants exercisable for up to $99 million. The funding will accelerate the development of Propanc's clinical pipeline and leverage Hexstone's experience in Digital Asset Treasury companies. The goal is to grow the treasury to $100 million within 12 months.